Receive The Newest Study Notifications

Emmaus Life Sciences Reinforces Positive Outcomes of Endari ® Clinical Trials, Including Efficacy Findings That Led to FDA Approval

by Lance Smith | Sep 24, 2019 | Study Scavenger Clinical Trial Recruitment Platform

d Journal of Medicine in 20181. Additionally, please visit the “CEO Letters” section of the Emmaus Life Sciences website to stay informed of corporate updates and remarks: https://www.emmausmedical.com/content/ceoletters/ceo-letter-sep-10-2019-193...

Kadimastem Announces Promising Interim Results of Cohort A of Its Phase 1/2a Clinical Trial in ALS

by Lance Smith | Sep 24, 2019 | Study Scavenger Clinical Trial Recruitment Platform

NESS ZIONA, Israel, Sept. 24, 2019 /PRNewswire/ — Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, today announced promising interim results of cohort A of its Phase 1/2a clinical trial for the treatment of patients with Amyotrophic Lateral...

Ocular Therapeutix™ Announces First Patient Dosed in Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Allergic Conjunctivitis

by Lance Smith | Sep 24, 2019 | Study Scavenger Clinical Trial Recruitment Platform

BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has...

Ocular Therapeutix™ Announces First Patient Dosed in Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Allergic Conjunctivitis

by Lance Smith | Sep 24, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Ocular Therapeutix™, Inc. (OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has dosed the first patients in its Phase 3 clinical...

Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX‑102) for the Treatment of Fabry Disease

by Lance Smith | Sep 24, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Phase III BALANCE study now fully enrolled BLA submission anticipated in Q1 2020 through FDA accelerated approval pathway    CARMIEL, Israel, Sept. 24, 2019 /PRNewswire/ — Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical...

Soricimed Announces Initiation of Patient Dosing for First Cohort in Investigator-Initiated Phase 1b Clinical trial of SOR-C13

by Lance Smith | Sep 24, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Soricimed Biopharma Inc. (“Soricimed”), a clinical-stage pharmaceutical company developing first-in-class, targeted cancer therapeutics, today announced that MD Anderson Cancer Center (“MDACC”) has completed enrolment and begun dosing the first...